Christian Andres Bermudez

Christian Andres Bermudez

Auto-generated profile, based on publicly available information

Christian Andres Bermudez

Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
MSMadhurmeet Singh
Madhurmeet Singh
MSMichael Shullo
Michael Shullo
RKRobert L. Kormos
Robert L. Kormos
KLKathleen Lockard
Kathleen Lockard
RZRachelle Zomak
Rachelle Zomak
JTJeffrey J. Teuteberg
Jeffrey J. Teuteberg
Renal dysfunction is common before mechanical circulatory support (MCS). Mechanical circulatory support frequently improves renal function, but the impact of pre-MCS renal dysfunction on renal function after cardiac transplantation (CTX) is unknown. Patients with MCS from January 1995 until April 2008 at a single center were included if their MCS duration was at least 60 days and they underwent successful CTX. Patients were followed for 1 year after CTX. A total of 116 patients were included in the study. Mechanical circulatory support was biventricular assist device in 28% and left ventricular assist device in 72% (continuous flow left ventricular assist device, 14%). Mean duration of MCS was 124 days. Patients were grouped according to tertiles of pre-MCS creatinine clearance (CrCl): group 1, CrCl less than 45 mL/min; group 2, CrCl between 45 and 65 mL/min inclusive; and group 3, CrCl more than 65 mL/min. Group 3 had the best renal outcomes both after MCS and 1 year after CTX. Regardless of group, patients who had a CrCl of at least 60 mL/min before CTX had similar 1-year posttransplant CrCl (55 versus 53 versus 56 mL/min for groups 1 through 3, respectively; not significantly different). However, the ability to achieve this level of renal function after MCS was less likely in those with the worst renal function before the initiation of MCS (53% versus 74% versus 90% for groups 1 through 3, respectively; p=0.001). The use of MCS leads to improvements in renal function in patients after MCS. However, the renal outcomes after CTX seem to be more dependent on the level of renal function achieved during MCS than on the level of renal function before MCS.

31 January 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
GZGan Zhao
Gan Zhao
LXLulu Xue
Lulu Xue
AWAaron I. Weiner
Aaron I. Weiner
NGNingqiang Gong
Ningqiang Gong
SAStephanie Adams-Tzivelekidis
Stephanie Adams-Tzivelekidis
AVAndrew E. Vaughan
Andrew E. Vaughan
Disruption of pulmonary vascular homeostasis is a central feature of viral pneumonia, wherein endothelial cell (EC) death and subsequent angiogenic responses are critical determinants of the outcome of severe lung injury. A more granular understanding of the fundamental mechanisms driving reconstitution of lung endothelium is necessary to facilitate therapeutic vascular repair. Here, we demonstrated that TGF-β signaling through TGF-βR2 (transforming growth factor–β receptor 2) is activated in pulmonary ECs upon influenza infection, and mice deficient in endothelial Tgfbr2 exhibited prolonged injury and diminished vascular repair. Loss of endothelial Tgfbr2 prevented autocrine Vegfa (vascular endothelial growth factor α) expression, reduced endothelial proliferation, and impaired renewal of aerocytes thought to be critical for alveolar gas exchange. Angiogenic responses through TGF-βR2 were attributable to leucine-rich α-2-glycoprotein 1, a proangiogenic factor that counterbalances canonical angiostatic TGF-β signaling. Further, we developed a lipid nanoparticle that targets the pulmonary endothelium, Lung-LNP (LuLNP). Delivery of Vegfa mRNA, a critical TGF-βR2 downstream effector, by LuLNPs improved the impaired regeneration phenotype of EC Tgfbr2 deficiency during influenza injury. These studies defined a role for TGF-βR2 in lung endothelial repair and demonstrated efficacy of an efficient and safe endothelial-targeted LNP capable of delivering therapeutic mRNA cargo for vascular repair in influenza infection.

1 November 2020 in Chest
Verified
Journal Article
Closed access
FSFederico Sertic
Federico Sertic
JHJason Han
Jason Han
DDDieynaba Diagne
Dieynaba Diagne
TRThomas Richards
Thomas Richards
LCLexy Chavez
Lexy Chavez
CBChristian A. Bermudez
Christian A. Bermudez

1 October 2020 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Andreas HabertheuerAndreas Habertheuer
Andreas Habertheuer
TRThomas Richards
Thomas Richards
FSFederico Sertic
Federico Sertic
MMMaria Molina
Maria Molina
PVPrashanth Vallabhajosyula
Prashanth Vallabhajosyula
CBChristian A. Bermudez
Christian A. Bermudez

20 January 2021 in Shock
Verified
Journal Article
Closed access
RBRene S. Bermea
Rene S. Bermea
YRYuval Raz
Yuval Raz
FSFederico Sertic
Federico Sertic
JRJonah Rubin
Jonah Rubin
MWMolly Wolf
Molly Wolf
CBChristian Bermudez
Christian Bermudez
COVID-19-related coagulopathy is a known complication of SARS-CoV-2 infection and can lead to intracranial hemorrhage (ICH), one of the most feared complications of extracorporeal membrane oxygenation (ECMO). We sought to evaluate the incidence and etiology of ICH in patients with COVID-19 requiring ECMO. Patients at two academic medical centers with COVID-19 who required venovenous-ECMO support for acute respiratory distress syndrome (ARDS) were evaluated retrospectively. During the study period, 33 patients required ECMO support; 16 (48.5%) were discharged alive, 13 died (39.4%), and 4 (12.1%) had ongoing care. Eleven patients had ICH (33.3%). All ICH events occurred in patients who received intravenous anticoagulation. The ICH group had higher C-reactive protein (P = 0.04), procalcitonin levels (P = 0.02), and IL-6 levels (P = 0.05), lower blood pH before and after ECMO (P < 0.01), and higher activated partial thromboplastin times throughout the hospital stay (P < 0.0001). ICH-free survival was lower in COVID-19 patients than in patients on ECMO for ARDS caused by other viruses (49% vs. 79%, P = 0.02). In conclusion, patients with COVID-19 can be successfully bridged to recovery using ECMO but may suffer higher rates of ICH compared to those with other viral respiratory infections.

1 November 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
CBChristian A Bermudez
Christian A Bermudez
MCMaria M. Crespo
Maria M. Crespo
OSOksana A. Shlobin
Oksana A. Shlobin
ECEdward Cantu
Edward Cantu
JMJeremy A. Mazurek
Jeremy A. Mazurek
OMOlaf Mercier
Olaf Mercier